Business Development Associate, Asimov

Salary not provided
Mid level
Remote in UK
Asimov

Intelligent genetic design platform

Open for applications

Asimov

Intelligent genetic design platform

21-100 employees

B2BArtificial IntelligenceDeep TechBiologyMachine LearningScience

Open for applications

Salary not provided
Mid level
Remote in UK

21-100 employees

B2BArtificial IntelligenceDeep TechBiologyMachine LearningScience

Company mission

To empower the genetic designers who are building the future.

Company mission

To empower the genetic designers who are building the future.

Top investors

41% employee growth in 12 months

Our take

Despite the many recent breakthroughs in medicine, drug manufacturing remains a lengthy and costly process that is difficult to scale. Asimov seeks to combat this with its intelligent design suite for synthetic biologists, that leverages computer-aided design to help design, simulate, and optimise genetic systems more reliably.

Asimov's platform consists of a fully integrated suite of cells, genes, and software that can be implemented in every step of the therapeutics creation process from initial design through to analysis. By accelerating the speed at which biologists can test and improve their drugs, the company has hopes to help bring innovative treatments to market faster and thus advance the standard of treatment for patients.

Having secured considerable funding, Asimov is looking to scale its business in biologics, advanced cell/gene therapies, and RNA. It will also use the investment to expand research and development into new areas of synthesis, as well as grow its team.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Company values

  • Recombination - Genetic engineering recombines genes from different species into new systems. At Asimov, we're working toward an ambitious mission that will only be possible by recombining disciplines, backgrounds, and perspectives
  • Mission first - Our prime directive is to radically advance humanity’s ability to design living systems, enabling biological technologies with outsized societal benefit. Every decision flows from this mission
  • Continuous learning - Biotech is advancing rapidly – we’re surfing that wave and also helping drive it forward. A curiosity to learn new things and an ability to teach other team members is critical to living at the cutting edge
  • Thoughtful communication - Our team comes from varied technical domains; we constantly strive to consider people's backgrounds, tailoring our communication to maximize understanding and alignment
  • Evolution - As we grow, we’re unafraid to evolve, adapt, and improve all aspects of our company's technology, products, and operations. We must avoid getting trapped in a local optimum

Funding (last 2 of 3 rounds)

Jan 2023

$175m

SERIES B

Dec 2019

$25m

SERIES A

Total funding: $204.7m

This company has top investors

Leadership

Chris Voigt

(Co-Founder)

Board Member at the Novo Nordisk Foundation, MIT Professor, and Co-Founder of Pivot Bio.

Douglas Densmore

(Co-Founder)

Professor at Boston University. Previously co-founded BioSens8 and Lattice Automation.

Job (1)

All locations

Sales & Account Management